Clinical Study of ET190L1 ARTEMIS™ in Relapsed, Refractory B Cell Lymphoma
Condition(s):Lymphoma, B-CellLast Updated:March 16, 2021Completed
Hide Studies Not Open or Pending
Condition(s):Lymphoma, B-CellLast Updated:March 16, 2021Completed
Condition(s):Lymphoma, B-CellLast Updated:October 5, 2021Withdrawn
Condition(s):Lymphoma, B-CellLast Updated:April 7, 2022Recruiting
Condition(s):Lymphoma, B-CellLast Updated:December 14, 2022Not yet recruiting
Condition(s):Lymphoma, B-CellLast Updated:February 7, 2024Recruiting
Condition(s):Lymphoma, B-CellLast Updated:November 15, 2019Unknown status
Condition(s):Lymphoma, B-CellLast Updated:December 29, 2023Recruiting
Condition(s):Lymphoma, B-CellLast Updated:February 23, 2022Withdrawn
Condition(s):Lymphoma, B-CellLast Updated:March 13, 2024Recruiting
Condition(s):Lymphoma, B-CellLast Updated:November 22, 2019Unknown status
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.